These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

121 related articles for article (PubMed ID: 9807679)

  • 1. Performance characteristics of a new synthetic APTT reagent.
    Ts'ao C; Neofotistos D; Oropeza M; Rogan M; Santos M
    Clin Lab Haematol; 1998 Oct; 20(5):307-13. PubMed ID: 9807679
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Assessment of Actin FS and Actin FSL sensitivity to specific clotting factor deficiencies.
    Lawrie AS; Kitchen S; Purdy G; Mackie IJ; Preston FE; Machin SJ
    Clin Lab Haematol; 1998 Jun; 20(3):179-86. PubMed ID: 9681235
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Activated partial thromboplastin time reagents: an evaluation.
    Howarth S
    Br J Biomed Sci; 1993 Jun; 50(2):109-13. PubMed ID: 8219915
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A rapid screen for lupus anticoagulant with good discrimination from oral anticoagulants, congenital factor deficiency and heparin, is provided by comparing a sensitive and an insensitive APTT reagent.
    Brancaccio V; Ames PR; Glynn J; Iannaccone L; Mackie IJ
    Blood Coagul Fibrinolysis; 1997 Apr; 8(3):155-60. PubMed ID: 9167015
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Performance of Activated Partial Thromboplastin Time (APTT): Determining Reagent Sensitivity to Factor Deficiencies, Heparin, and Lupus Anticoagulants.
    Kershaw G
    Methods Mol Biol; 2017; 1646():75-83. PubMed ID: 28804819
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A comparison of two APTT reagents which use silica activators.
    Ray MJ; Hawson GA
    Clin Lab Haematol; 1989; 11(3):221-32. PubMed ID: 2556232
    [TBL] [Abstract][Full Text] [Related]  

  • 7. How to Optimize Activated Partial Thromboplastin Time (APTT) Testing: Solutions to Establishing and Verifying Normal Reference Intervals and Assessing APTT Reagents for Sensitivity to Heparin, Lupus Anticoagulant, and Clotting Factors.
    Favaloro EJ; Kershaw G; Mohammed S; Lippi G
    Semin Thromb Hemost; 2019 Feb; 45(1):22-35. PubMed ID: 30630206
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Recommendations for appropriate activated partial thromboplastin time reagent selection and utilization.
    Fritsma GA; Dembitzer FR; Randhawa A; Marques MB; Van Cott EM; Adcock-Funk D; Peerschke EI
    Am J Clin Pathol; 2012 Jun; 137(6):904-8. PubMed ID: 22586049
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Establishing a new target range for unfractionated heparin for acute coronary syndromes.
    Lee MS; Menon V; Schappert J; Wilentz JR; Singh V; Hochman JS
    J Thromb Thrombolysis; 2004 Apr; 17(2):121-6. PubMed ID: 15306747
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Verification of the guidelines for lupus anticoagulant detection: usefulness of index for circulating anticoagulant in APTT mixing test.
    Kumano O; Ieko M; Naito S; Yoshida M; Takahashi N; Suzuki T; Aoki T
    Thromb Res; 2014 Aug; 134(2):503-9. PubMed ID: 24935674
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Comparison of four commercially available activated partial thromboplastin time reagents using a semi-automated coagulometer.
    Shetty S; Ghosh K; Mohanty D
    Blood Coagul Fibrinolysis; 2003 Jul; 14(5):493-7. PubMed ID: 12851537
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Evaluation of the Q analyzer, a new cap-piercing fully automated coagulometer with clotting, chromogenic, and immunoturbidometric capability.
    Kitchen S; Woolley A
    Blood Coagul Fibrinolysis; 2013 Jan; 24(1):28-34. PubMed ID: 23249565
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Variability in heparin sensitivity of APTT reagents.
    Bjornsson TD; Nash PV
    Am J Clin Pathol; 1986 Aug; 86(2):199-204. PubMed ID: 3739971
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Sensitivity of sixteen APTT reagents for the presence of lupus anticoagulants.
    Denis-Magdelaine A; Flahault A; Verdy E
    Haemostasis; 1995; 25(3):98-105. PubMed ID: 7607585
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Usefulness of cumulative summation of differences method for determining APTT reagent suitability.
    Findlater SH
    Clin Lab Sci; 2012; 25(3):142-8. PubMed ID: 22953513
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Limitation of the activated partial thromboplastin time as a monitoring method of the direct thrombin inhibitor argatroban.
    Guy S; Kitchen S; Maclean R; Van Veen JJ
    Int J Lab Hematol; 2015 Dec; 37(6):834-43. PubMed ID: 26305560
    [TBL] [Abstract][Full Text] [Related]  

  • 17. In vitro sensitivity of different activated partial thromboplastin time reagents to mild clotting factor deficiencies.
    Toulon P; Eloit Y; Smahi M; Sigaud C; Jambou D; Fischer F; Appert-Flory A
    Int J Lab Hematol; 2016 Aug; 38(4):389-96. PubMed ID: 27185477
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Usefulness of synthetic phospholipid in measurement of activated partial thromboplastin time: a new preparation procedure to reduce batch difference.
    Okuda M; Yamamoto Y
    Clin Lab Haematol; 2004 Jun; 26(3):215-23. PubMed ID: 15163321
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The therapeutic range for heparin therapy: relationship between six activated partial thromboplastin time reagents and two heparin assays.
    Kitchen S; Preston FE
    Thromb Haemost; 1996 May; 75(5):734-9. PubMed ID: 8725715
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Two different incubation times for the activated partial thromboplastin time (APTT): a new criterion for diagnosis of lupus anticoagulant.
    Robert A
    Thromb Haemost; 1994 Feb; 71(2):220-4. PubMed ID: 8191402
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.